KRAS and non-small cell lung carcinoma: Our data showed that bortezomib could also serve as an effective cell cycle inhibitor for NSCLC with different driven mutations (KRAS G12C/V mutations, EGFR mutation and ALK fusion) and TKIs resistance (osimertinib resistance and lorlatinib resistance).